O-mannosylation and N-glycosylation: Two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer by Carvalho, S et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
O–mannosylation and N-glycosylation: two coordinated 
mechanisms regulating the tumour suppressor functions of 
E-cadherin in cancer
Sandra Carvalho1,2,*, Tiago Oliveira1,*, Markus F. Bartels3, Eiji Miyoshi4, Michael 
Pierce5, Naoyuki Taniguchi6, Fátima Carneiro1,7,8, Raquel Seruca1,8, Celso A. Reis1,2,8, 
Sabine Strahl3, Salomé S. Pinho1,7
1Instituto de Investigação e Inovação em Saúde (I3S) / Institute of Molecular Pathology and Immunology of the University 
of Porto (IPATIMUP), 4200-465 Porto, Portugal
2Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
3Centre for Organismal Studies (COS) Heidelberg, Cell Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
4Molecular Biochemistry and Clinical Investigation Department, Osaka University Graduate School of Medicine, 565-0871 
Osaka, Japan
5Complex Carbohydrate Research Center, Department of Biochemistry and Molecular Biology of University of Georgia, 
Athens, GA 30602, USA
6Department of Biochemistry, Graduate School of Medicine, Osaka University, 565-0871 Osaka, Japan
7Medical Faculty, University of Porto, 4200-319 Porto, Portugal
8Department of Pathology, Hospital S. Joao, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
*These authors have contributed equally to this work
Correspondence to: Salomé S. Pinho, email: salomep@ipatimup.pt
Keywords: E-cadherin, O-mannosylation, N-glycosylation, gastric cancer
Received: May 09, 2016    Accepted: August 01, 2016    Published: August 12, 2016
ABSTRACT
Dysregulation of tumor suppressor protein E-cadherin is an early molecular 
event in cancer. O-mannosylation profile of E-cadherin is a newly-described post-
translational modification crucial for its adhesive functions in homeostasis. However, 
the role of O-mannosyl glycans in E-cadherin-mediated cell adhesion in cancer and 
their interplay with N-glycans remains largely unknown. We herein demonstrated 
that human gastric carcinomas exhibiting a non-functional E-cadherin display a 
reduced expression of O-mannosyl glycans concomitantly with increased modification 
with branched complex N-glycans. Accordingly, overexpression of MGAT5-mediated 
branched N-glycans both in gastric cancer cells and transgenic mice models led to a 
significant decrease of O-mannosyl glycans attached to E-cadherin that was associated 
with impairment of its tumour suppressive functions. Importantly, overexpression of 
protein O-mannosyltransferase 2 (POMT2) induced a reduced expression of branched 
N-glycans which led to a protective effect of E-cadherin biological functions. Overall, 
our results reveal a newly identified mechanism of (dys)regulation of E-cadherin that 
occur through the interplay between O-mannosylation and N-glycosylation pathway.
INTRODUCTION
Epithelial cadherin (E-cadherin) is a cell surface 
glycoprotein with key roles in normal epithelial 
homeostasis, cell polarity and tissue architecture [1–3]. 
E-cadherin extracellular domain mediates homophilic 
interactions between neighbouring cells [4, 5] while 
the E-cadherin cytoplasmic domain binds to cytosolic 
catenins, namely β-catenin and p-120 catenin, providing 
anchorage to the actin cytoskeleton and contributing to the 
establishment of stable and mature adhesion complexes- 
adherens junctions [6, 7]. Reduced expression of E-cadherin 
and impairment of its functions are well-established 
molecular events that occur during tumour development 
and progression, leading to an increased ability of cells to 
invade surrounding tissues and to metastasize [8–10].
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Aberrant glycosylation occurs in essentially all 
types of human cancers, and thus numerous glycans 
epitopes constitute tumour-associated antigens 
[11]. Posttranslational modifications of E-cadherin 
through glycosylation play an instrumental role in the 
dysregulation of E-cadherin functions in a cancer context 
[12–14]. As example, O-linked β-N-acetylglucosamine 
(O-GlcNAc) modification of the E-cadherin cytoplasmic 
domain was described to retain E-cadherin in the 
endoplasmic reticulum (ER) inhibiting its trafficking to the 
plasma membrane, and resulting in reduced intercellular 
adhesion [15, 16]. An O-N-acetylgalactosamine 
(O-GalNAc) glycosite on EC1 ecdomain of E-cadherin 
was additionally reported [17]. In fact, altered pattern 
of protein glycosylation results in the production of 
different E-cadherin glycoforms that are associated with 
impairment of its crucial functions in gastric cancer [18].
Modification of E-cadherin with β1,6 
GlcNAc branched N-glycans, induced by the 
N-acetylglucosaminyltransferase V (GnT-V), has 
deleterious effects on E-cadherin-mediated cell adhesion 
leading to the impairment of the stability and competence of 
the intercellular adhesive complex [18–20]. The importance 
of this specific E-cadherin N-glycoform was demonstrated 
to be associated with the invasive and metastatic potential of 
gastric carcinoma [18]. Moreover, it was recently reported 
that among the four potential N-glycosylation sites on the 
extracellular domain of E-cadherin, Asn-554 is the key 
N-glycosylation site that, within a gastric cancer context, 
is selectively modified with the deleterious β1,6 GlcNAc 
branched N-glycans, and directly affects E-cadherin 
functions [21]. Importantly, prevention of E-cadherin 
aberrant glycosylation at Asn-554 was found to preclude 
its functional dysregulation in gastric cancer cell models by 
improving its cell adhesion functions [21].
Protein O-mannosylation is a posttranslational 
process initiated at the ER by the covalent attachment 
of mannose structures to serine (Ser) or threonine 
(Thr) amino acids of secretory and/or membrane 
proteins, catalysed by the homologous protein 
O-mannosyltransferases 1 (POMT1) and 2 (POMT2) 
[22–24]. The mannose residue linked to Ser/Thr may be 
then further extended with different carbohydrate moieties 
originating distinct O-mannosyl oligosaccharides [25]. 
N-acetylglycosaminyltransferase IX (GnT-IX or GnT-
Vb [26]) has been identified to be involved in further 
extension of the O-mannosyl glycans core structures 
after POMGnT1 activity in α-dystroglycan (α-DG) 
glycoprotein in the brain [27, 28]. α-DG is an integral 
glycoprotein of the dystrophin-glycoprotein complex that 
undergoes O-mannose and mucin-type O-glycosylation 
[29]. The α-DG links the extracellular matrix (ECM) to 
the actin cytoskeleton by interacting with ECM proteins 
in a glycan-dependent manner [30, 31]. Disruption of the 
O-mannosylation pathway, and thus the hypoglycosylation 
of α-DG result in the impairment of α-DG-mediated 
epithelial cell-basement membrane interaction [32], 
and underlies various forms of congenital muscular 
dystrophies (CMD) [33, 34].
A wide spectrum of other O-mannosylated proteins 
has been recently identified, and among them, cadherins 
were shown as major O-mannosylated glycoproteins 
[35, 36]. Vester-Christensen et al. identified nine O-Man 
glycosites located on EC2- EC4 ectodomains of E-cadherin 
[35] being some of these O-Man glycosites also found 
in the crystal structure of E-cadherin [37]. Furthermore, 
Lommel et al proved directly the presence of an O-linked 
mannose on ectodomain EC4 of E-cadherin that is not 
elongated further [36]. Defective O-mannosylation 
has been reported to affect the formation of adherens 
junctions between blastocysts of the mouse embryo and 
thus required for the morula to blastocyst transition before 
implantation [36]. Moreover, O-mannosylation was 
found to be important for E-cadherin-mediated cellular 
adhesion in non-cancer cellular models [36]. Taking into 
consideration the instrumental role of glycosylation as a 
mechanism for regulating E-cadherin functions in cancer 
[12, 13], it is of utmost importance to understand the yet 
uncovered molecular role of O-mannosyl glycans and their 
interplay with N-glycans in the regulation of E-cadherin in 
the context of cancer.
In this study, we originally report that 
O-mannosylation is overall reduced in human gastric 
cancer when compared with normal gastric mucosa, 
by affecting the capacity of E-cadherin to establish 
competent adhesive complexes. Furthermore, we also 
demonstrate the existence of a coordinated interplay 
between complex N-glycans and O-mannosyl glycans on 
E-cadherin with biological relevance in a cancer context. 
Interestingly, preventing the addition of β1,6-GlcNAc-
branched N-glycans at the E-cadherin Asn-554 promotes 
its modification with O-mannosyl glycans, leading to a 
recovery of E-cadherin functions. Further, this interplay 
between branched N-glycans and O-mannosyl glycans 
was found to occur in vivo using human primary gastric 
carcinomas and experimental animal models.
RESULTS
Protein O-mannosylation is reduced in primary 
human gastric carcinomas
We sought to understand whether the dysregulation 
of O-mannosylation process is an important oncogenic 
event in diffuse gastric cancer. We used a unique cohort 
of well-characterized human primary diffuse gastric 
carcinomas from the pathology department of Hospital São 
João, Porto, Portugal, considered an international reference 
in gastropathology. The expression of O-mannosylated 
proteins was assessed in 18 well-characterized human 
primary diffuse gastric carcinomas displaying aberrant 
E-cadherin expression (not due to genetic/structural 
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alterations). Such analysis was performed by using a 
rabbit monoclonal antibody (mAb) generated to direct 
against a threonine O-mannosyl-conjugated epitope and 
specifically detects O-mannosylated proteins (unpublished 
data) [36]. Normal gastric mucosa, displaying a normal 
basolateral cell membrane localization of E-cadherin, 
exhibited a strong reactivity to T[α1-Man] mAb both 
at the cytoplasm (staining the ER and Golgi secretory 
pathway) and cell membrane (Figure 1A). Conversely, 
in gastric cancer cases showing an abnormal pattern of 
Figure 1: Expression of E-cadherin and O-mannosyl glycans in human normal gastric mucosa and diffuse gastric 
cancer. A. Immunodetection of E-cadherin and O-mannosylated proteins. Immunohistochemical analysis of the normal gastric mucosa (n= 
10) showed membrane E-cadherin expression, as expected. T[α1-Man] immunohistochemistry detecting threonine O-mannosyl-conjugated 
epitopes revealed a strong intracellular staining of O-mannosylated proteins (black arrow) and at the cell membrane (white arrowhead) in 
the body region of the normal gastric mucosa. Almost no reactivity to T[α1-Man] mAb in neoplastic cells displaying an aberrant expression 
of E-cadherin at the cytoplasm was observed (n= 18). However, intact glands of adjacent non-neoplastic mucosa with membrane E-cadherin 
expression exhibited intracellular staining of O-mannosylated proteins, although less intense than normal gastric body mucosa. Original 
magnification: 600x. B. Evaluation of O-mannosyl glycan levels in total lysates from normal gastric mucosa and diffuse gastric carcinoma 
tissues by lectin blotting. To evaluate the expression of O-mannosyl glycans, a blotting using Con A mannose-binding lectin was performed. 
Con A lectin recognizes α-linked mannose residues from O-mannosylated proteins and N-glycoproteins. So, tissue lysates were treated with 
PNGase F to remove all types of N-glycans before the lectin blotting (see Material and methods´ section). As expected, PNGase F treatment 
resulted in a decreased reactivity to the Con A lectin. Regarding the expression of O-mannosyl glycans (detected by treatment with PNGase 
F + Con A lectin blotting), diffuse gastric carcinoma displayed a decreased O-mannosylation profile. Blot represents two independent 
biological experiments. Each experiment was performed from the total lysates pooled from different patients and then analyzed as one 
sample. The same procedure was performed in the second experiment. WB, Western blot.
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E-cadherin expression, the levels of O-mannosylated 
glycoproteins decreased significantly. Interestingly, 
threonine O-mannosyl-conjugated epitopes were detected 
in adjacent non-neoplastic mucosa, predominantly in cells 
displaying a cell membrane localization of E-cadherin 
(Figure 1A). Our results point toward a strong association 
between increased protein O-mannosylation in normal/
homeostatic conditions, that is significantly reduced in 
diffuse gastric carcinomas with aberrant expression of 
E-cadherin (p value 7.34 x 10-6, Table 1).
We also evaluated the O-mannosyl glycan profile 
of total tissue lysates from normal gastric mucosa and 
gastric carcinoma by using the Concanavalin A (Con 
A) lectin after previous removal of all type of N-linked 
glycans (high mannose, hybrid and complex type) by 
PNGase F treatment. As shown in Figure 1B, the overall 
O-mannosylation profile is decreased in human primary 
gastric cancer samples. These observations suggest 
that primary gastric carcinoma displays low levels of 
O-mannosylated glycoproteins.
Aberrant E-cadherin expression associated with 
decreased O-mannosylation in cancer
To further evaluate the impact of O-mannosylation 
in E-cadherin, we investigated the expression of 
O-mannosyl glycans in two distinct gastric cancer cell 
lines with different E-cadherin expression patterns: 
MKN28 gastric cancer cell line which display normal 
E-cadherin expression, and Kato III gastric cancer cell 
line which exhibit an abnormal E-cadherin expression 
[38–40]. According to Figure 2A, MKN28 cells 
exhibited a strong membranous staining of E-cadherin 
(upper panel), high capacity to form large compact 
cellular aggregates (medial panel) and an epithelial cell 
morphology (lower panel). In contrast, Kato III cell line 
is characterized by a reduced E-cadherin expression with 
some mislocalization into the cytoplasm, reduced cell-
cell aggregation capability and a sparsely and rounded 
cellular morphology.
Concerning POMT2 expression levels, a decrease in 
the steady-state protein level of POMT2 was observed in 
Kato III cells when compared to MKN28 cells (Figure 2B). 
Concordantly, lower levels of POMT2 mRNA transcripts 
were detected in Kato III cells (Figure 2C). No significant 
differences were observed for POMT1 transcription 
levels (Supplementary Figure S1A). In addition, the 
undifferentiated gastric cancer cell line Kato III exhibited 
a distinct pattern of O-mannosylation (evaluated by Con 
A lectin blotting after removal of all type of N-glycans 
by PNGase F digestion) when compared with the well-
differentiated MKN28 cells (Figure 2B, Supplementary 
Figure S1B).
Having demonstrated an association between 
decreased POMT2 expression (at protein and transcript 
level) and a distinct pattern of O-mannosyl glycans 
in gastric cancer cells displaying different E-cadherin 
expression patterns, we further evaluated the expression 
of O-mannosyl glycans specifically on the E-cadherin 
protein. As depicted in Figure 2D, E-cadherin from 
MKN28 cells showed a significantly increased reactivity 
to the Con A- mannose binding lectin (after release of 
N-glycans), when compared with E-cadherin from Kato 
III (Supplementary Figure S1C). The expression of other 
glycosylation types, such as O-GlcNAc and mucin-type 
O-glycosylation (Sialyl Tn) on E-cadherin in these two 
gastric cancer cell lines are represented in Supplementary 
Figure S1C-S1D.
These results strongly indicate that functional 
E-cadherin (expressed at the cell membrane) is highly 
O-mannosylated whereas aberrant E-cadherin displays low 
levels of O-mannosyl glycans.
POMT2 expression impacts O-mannosylation of 
E-cadherin regulating its biological functions in 
cancer
We further evaluated the impact of O-mannosylation 
on the pattern of E-cadherin expression and its molecular 
interaction with its cytoplasmic partners by silencing 
POMT2 in MKN28 cells (Figure 3) or by overexpressing 
POMT2 in Kato III cells (Figure 4).
POMT2 silencing in MKN28 cell line resulted 
in a significant reduction of POMT2 mRNA transcripts 
and decreased POMT2 protein levels (Figure 3A–3B). 
The impact of POMT2 knockdown on E-cadherin 
O-mannosylation is not as remarkable as expected 
(Figure 3C) (p value = 0.05), which may suggest 
other compensatory mechanisms on the process of 
O-mannosylation of E-cadherin. Interestingly, POMT2 
knockdown resulted in an abnormal E-cadherin 
localization at the cell membrane with a punctuated 
membrane staining and altered cell morphology (Figure 
3D). We further evaluated the impact of decreased 
O-mannosylation in the assembly and stability of the 
cadherin-catenin complex. The results showed that 
POMT2 knockdown led to a significant decreased 
interaction of E-cadherin with p120-catenin (Figure 3E). 
No significant differences were observed regarding the 
recruitment of β-catenin by E-cadherin upon POMT2 
silencing. Overall, these results indicate that POMT2 
knockdown impairs the E-cadherin membrane stability, 
and disturbs the assembly of the adherens junctions 
through a decreased recruitment of p-120 catenin by 
E-cadherin.
Overexpression of POMT2 in the undifferentiated 
Kato III cells (confirmed at mRNA and protein 
levels- Figure 4A-4B) led to a significant increased 
modification of E-cadherin with O-mannosyl glycans 
(Figure 4C). Furthermore, the increased E-cadherin 
O-mannosylation was accompanied with a E-cadherin 
expression at the cell-cell borders (Figure 4D), and 
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Table 1: Expression of O-mannosylated proteins in healthy and diffuse gastric cancer patients
O-mannosylated protein expression P value
Negative Low (< 20%) High (> 20%)
No of patients (%)
Normal gastric mucosa 0/10 (0%) 2/10 (20%) 8/10 (80%) 7.34 × 10−6***
Diffuse gastric cancer 16/18 (89%) 2/18 (0.11%) 0/18 (0%)
Figure 2: E-cadherin O-mannosylation decreases in undifferentiated gastric cancer cells. A. E-cadherin localization, cell 
aggregation capacity and morphology in MKN28 and Kato III cell lines. MKN28 cells are characterized by a functional E-cadherin 
expression at the cell membrane (arrowhead), a high capacity to form large compact cell aggregates and an epithelial cell morphology. In 
contrast, Kato III cells displayed a reduced expression of E-cadherin at the cell-cell contacts with some mislocalization into the cytoplasm 
(arrow), decreased cell aggregation capacity and a sparse and rounded morphology. White size bars indicates 5µm. B. Evaluation of POMT2 
protein and O-mannosyl glycans expression in the total cell lysates from MKN28 and Kato III cells by Western blot and Con A lectin 
staining (which recognizes O-mannosyl glycans after remove of N-glycans by PNGase F digestion), respectively. A decrease of POMT2 
protein expression and a distinct O-mannosyl glycan pattern was observed in total cell lysate from Kato III, when compared with MKN28. 
WB (TCL), Western blot (total cell lysate). C. POMT2 mRNA expression. The amount of POMT2 transcripts was significantly decreased 
in Kato III cells (p value= 0.0293). Plot represents three independent biological experiments. D. E-cadherin O-mannosylation decreases 
in undifferentiated gastric cancer cell line. E-cadherin immunoprecipitated from Kato III cells showed decreased Con A lectin reactivity, 
after removal of N-linked glycans by PNGase F digestion, when compared with E-cadherin immunoprecipitated from MKN28 cells (4.4-
fold; p value= 0.0081). Bar graphs, amounts of O-mannosyl glycans on E-cadherin are shown as the ratio of densities of Con A lectin and 
E-cadherin protein reactivity. Results are described as mean ± s.d of three independent biological experiments. IP, immunoprecipitate.
Oncotarget6www.impactjournals.com/oncotarget
increased binding of E-cadherin to β-catenin and 
p-120-catenin (Figure 4E). These results suggest 
that O-mannosylation of E-cadherin is essential for 
its correct localization at the cell membrane and 
contributes for the stability of the adherens junctions in 
a gastric cancer context.
N-glycosylation and O-mannosylation processes 
as inter-players in the regulation of E-cadherin 
functions in cancer
Our previous studies demonstrated that addition of 
GnT-V-mediated β1,6 GlcNAc branched N-glycans on 
Figure 3: POMT2 knockdown impairs membrane E-cadherin localization and the assembly of the E-cadherin-catenin 
complex. A. POMT2 mRNA expression in MKN28 cells after POMT2 knockdown by the small interfering RNA (siRNA) technique. 
Around 75% of POMT2 silencing was observed (p value < 0.0001). NS, non-silencing. The relative POMT2 mRNA expression of siPOMT2 
cells is shown as the fold increase, compared with NS cells, which was taken as 1. Plot represents three independent biological replicates. 
B. POMT2 protein expression. POMT2 silencing resulted in a significant decreased expression of POMT2. C. POMT2 silencing resulted 
in a minor decreased Con A reactivity of the E-cadherin band after removal of N-glycans. Bar graphs, amounts of O-mannosyl glycans on 
E-cadherin were determined from the ratios of densities of lectin reactivity (with PNGase F treatment) after normalization (as in Figure 
2D). Results are described as mean ± s.d of two independent experiments. P value = 0.05. D. Immunofluorescence analysis of MKN28 
cells after POMT2 silencing demonstrated a reduced E-cadherin localization at the cell membrane and altered cell morphology. White 
size bars indicate 5µm. E. E-cadherin immunoprecipitation after POMT2 silencing. The co-immunoprecipitated proteins p-120-catenin 
and β-catenin were identified by western-blot. Knockdown of POMT2 resulted in a decreased interaction between E-cadherin and p-120-
catenin (of about 0.55-fold). No significant differences were observed regarding the interaction of E-cadherin with β-catenin. Amount of 
association with p-120-catenin and β-catenin were determined as the fold increase, compared with NS cells (which was taken as 1), after 
normalization to E-cadherin.
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E-cadherin contributed to the abrogation of its functions 
in cancer [18]. Furthermore, E-cadherin was shown to be 
a target of O-mannosylation being important for cadherin-
mediated cell adhesion [36]. Taking into consideration 
these previous observations, we went to evaluate the 
interplay between these two major forms of E-cadherin 
modifications: GnT-V-mediated N-glycosylation and O-
mannosylation.
The analysis of the transcript levels of MGAT5 
and POMT2 in these two distinct gastric cancer cell lines 
showed an inverse relationship: the decreased POMT2 
expression in the undifferentiated gastric cancer cells is 
Figure 4: POMT2 overexpression induces the recovery of E-cadherin biological functions. A. Confirmation of the overexpressed 
POMT2 mRNA transcripts in Kato III cells. The relative POMT2 mRNA expression is indicated as the fold increase, compared with 
mock cells, which was taken as 1. Plot represents three independent biological replicates. P value< 0.0001. B. Overexpression of POMT2 
increases the expression of POMT2 protein. C. Evaluation of the impact of POMT2 overexpression on E-cadherin O-mannosylation. POMT2 
overexpression led to a significant increased reactivity of immunoprecipitated E-cadherin to the Con A lectin (after PNGase F treatment), 
suggesting an increase of E-cadherin O-mannosylation (around 5.7- fold). Bar graphs, amounts of O-mannosyl glycans on E-cadherin were 
determined as in Fig. 2D. Results are described as mean ± s.d of two independent experiments. P value = 0.0376 D. Immunofluorescence 
analysis of Kato III cells overexpressing POMT2 demonstrated an increased localization of E-cadherin at cell-cell contact sites. White size 
bars correspond to 5µm. E. Evaluation of β-catenin and p-120-catenin recruitment by E-cadherin after POMT2 overexpression. Kato III 
cells displayed an increased interaction between E-cadherin and β-catenin and p-120-catenin (around 8.0-fold and 1.5-fold, respectively).
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accompanied with increased MGAT5 transcript levels, 
compared with the well-differentiated MKN28 cells that 
revealed the opposite (Figure 5A). The analysis of the 
expression of β1,6 GlcNAc branched N-glycans (detected 
by lectin phytohemagglutinin- L-PHA), and O-mannosyl 
glycans (evaluated by Con A lectin after removal of 
N-linked glycans) on E-cadherin showed that E-cadherin 
from MKN28 is modified with both glycans, whereas 
E-cadherin from a poorly-differentiated gastric cancer 
phenotype (Kato III) mainly exhibited positive reactivity 
to L-PHA lectin (Supplementary Figure S2A). Despite 
the reactivity of E-cadherin from MKN28 cells to the 
Con A lectin (after removal of N-glycans) is significantly 
higher than E-cadherin from Kato III cells (Figure 2D), 
no significant differences were verified regarding the 
E-cadherin N-glycosylation mediated by GnT-V (detected 
by reactivity to the L-PHA lectin) in these two cell lines.
Afterwards, we evaluated the influence of POMT2 
silencing or overexpression on the levels of β1,6 GlcNAc 
branched N-glycans of E-cadherin. POMT2 knockdown 
in MKN28 cells resulted in a significantly increased 
expression of β1,6 GlcNAc branched N-glycans on 
E-cadherin (Figure 5B), although a slight decrease of 
MGAT5 transcripts was observed (Supplementary Figure 
S2B). Conversely, the overexpression of POMT2 in Kato 
III cells led to a significant decrease of MGAT5 mRNA 
expression (Supplementary Figure S2C), but no significant 
differences in β1,6 branched N-glycans on E-cadherin 
were found (Figure 5C).
In addition, and to further clarify this potential 
interplay between branched N-glycans and O-mannosyl 
glycans on E-cadherin we used the MKN45 gastric 
cancer cell line stably transfected with MGAT5 [18, 41]. 
According to Figure 5D, overexpression of MGAT5 leads 
to a significantly increased modification of E-cadherin 
with GnT-V-mediated branched N-glycans, concomitantly 
with a significant decrease of O-mannosyl glycans. No 
significant differences were observed on POMT2 mRNA 
expression after MGAT5 overexpression (Supplementary 
Figure S2D). Taken together, these results suggest that, 
despite no strict correlation between mRNA levels of 
POMT2 and MGAT5, there is an inverse relationship 
between E-cadherin N-glycosylation mediated by 
GnT-V and O-mannosylation that appears to occur at the 
E-cadherin post-translational level.
Impact of site-specific N-glycosylation on 
E-cadherin O-mannosylation
Recently, we demonstrated that among the four 
potential N-glycosylation sites of E-cadherin, Asn-554 
is the selected site modified with β1,6 GlcNAc branched 
N-glycans resulting in deleterious effects on E-cadherin 
functions in cancer [21]. Moreover, we also reported 
that preventing this aberrant glycosylation mediated by 
GnT-V at Asn-554 resulted in a recovery of E-cadherin 
biological functions in cancer [21]. In order to evaluate 
the relationship between E-cadherin O-mannosylation 
and E-cadherin site-specific N-glycosylation, we analyzed 
the expression of O-mannosyl glycans on the different 
E-cadherin N-glycoforms: E-cadherin wild-type (WT), 
E-cadherin M1 (with Asn-554 abrogated) and E-cadherin 
M234 (with Asn-566, Asn-618 and Asn-633 abrogated) 
[21]. According to Figure 5E, E-cadherin M1 exhibited 
increased modification with O-mannosyl glycans, as 
detected by the higher reactivity to the Con A lectin (after 
removal of N-glycans) when compared to E-cadherin WT 
and E-cadherin M234. These results strongly support that 
deletion of Asn-554 (E-cadherin M1), which precludes 
the addition of β1,6 GlcNAc branched N-glycans at this 
specific site, is associated with an increased modification 
of E-cadherin with O-mannosyl glycans. Additionally, 
our results further showed that removal of N-glycans by 
PNGase F treatment leads to a lower mobility shift of 
E-cadherin WT and M1 band comparing with E-cadherin 
M234. These results indicated that these E-cadherin 
N-glycoforms may undergo further glycosylation 
modification while E-cadherin M234 does not, which 
support the results regarding Con A lectin blotting.
Inverse relationship between GnT-V-mediated 
N-glycosylation and O-mannosylation in the 
stomach of transgenic mice and primary human 
gastric carcinomas
In order to assess in vivo the biological relevance 
of GnT-V-mediated N-glycosylation/ O-mannosylation 
interplay we analyzed the expression of β1,6 GlcNAc 
branched N-glycans and O-mannosylated proteins in 
stomach paraffin samples from MGAT5 transgenic mice 
models and human gastric carcinomas clinical samples.
Previously, we have demonstrated that GnT-V-
mediated glycosylation was associated with an abnormal 
pattern of E-cadherin expression in the gastric mucosa of 
GnT-V transgenic mice [21]. Thus, we herein evaluated 
the correlation between the expression of GnT-V-mediated 
glycosylation and O-mannosylation in the gastric mucosa 
of MGAT5 knockout (KO) and MGAT5 overexpressing 
mice comparing with wild-type (Figure 6A). The results 
showed that gastric mucosa of MGAT5 KO, characterized 
by no reactivity to L-PHA lectin (no expression of β1,6 
GlcNAc branched N-glycans) and displaying a normal 
E-cadherin distribution in the basolateral cell membrane, 
showed overexpression of O-mannosylated proteins. 
On the other hand, mice overexpressing MGAT5 with a 
strong staining with L-PHA lectin and an aberrant pattern 
of E-cadherin expression, displayed reduced levels of 
O-mannosylated proteins. These results indicated that 
MGAT5 expression affects the protein O-mannosylation.
In human gastric cancer context, gastric mucosa 
from healthy patients consistently displays positive 
staining to the T[α1-Man] mAb that is accompanied with 
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Figure 5: Interplay between GnT-V-mediated N-glycosylation and POMT2-mediated O-mannosylation of E-cadherin 
in vitro. A. Evaluation of mRNA transcripts of POMT2 (p value = 0.011) and MGAT5 (p value = 0.0294) in MKN28 versus Kato III cells. 
Plot represents three independent biological replicates. B-D. Reactivity of E-cadherin immunoprecipitated from the different context of 
POMT2 and MGAT5 modulation to the lectins Con A (after removal of N-glycans) and L-PHA. Knockdown of POMT2 (B) resulted in 
increased levels of β1,6 GlcNAc branched N-glycans on E-cadherin (around 4.0-fold; p value =0.0250), whereas POMT2 overexpression 
(C) did not alter the reactivity of E-cadherin to L-PHA lectin. (D) Overexpression of MGAT5 in MKN45 cells resulted in an increased 
L-PHA lectin staining (1.85-fold; p value = 0.006) and a decreased reactivity to Con A lectin after PNGase F treatment (0.52-fold; p value 
< 0.0001). Bar graphs, amounts of β1,6 GlcNAc branched N-glycans and O-mannosyl glycans on E-cadherin were determined from the 
ratios of densities of L-PHA and Con A lectins reactivity respectively, after normalization to E-cadherin. E. Evaluation of E-cadherin O-
mannosylation regarding site-specific N-glycosylation occupancy. E-cadherin M1 immunoprecipitated exhibited an increased reactivity 
to Con A lectin (after PNGase F treatment) when compared with E-cadherin WT and mutant M234. Removal of N-glycans by PNGase 
F treatment lead to a lower mobility shift of E-cadherin WT and M1 band comparing with E-cadherin M234, which indicates that these 
E-cadherin N-glycoforms may undergo further modification while E-cadherin M234 does not.
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Figure 6: Interplay between GnT-V – mediated N-glycosylation and O-mannosylation in vivo. Expression of β1,6 GlcNAc 
branched N-glycans and O-mannosyl glycans in the gastric mucosa of MGAT5 knockout (KO) and MGAT5 overexpressing mice, and in 
human normal gastric mucosa versus diffuse gastric carcinoma. A. Histochemical analysis detecting β1,6 GlcNAc branched N-glycans 
showed an absent, a strong, and a moderate L-PHA lectin staining in the gastric mucosa of MGAT5 KO, MGAT5 transgenic, and WT mice, 
respectively. Concerning the T[α-Man] immunoreactivity, gastric mucosa from WT and MGAT5 transgenic mice showed low expression 
of O-mannosylated proteins. In contrast, a overexpression of O-mannosylated glycoproteins is verified in MGAT5 KO gastric mucosa. B. 
Interplay between GnT-V-mediated glycosylation and protein O-mannosylation in human gastric mucosa. L-PHA histochemistry showed 
almost no reactivity in the human normal gastric mucosa and a marked positivity in neoplastic cells from diffuse gastric carcinoma. 
Regarding the expression of O-mannosylated proteins, we verified that neoplastic cells from diffuse gastric carcinoma positive to L-PHA 
lectin and showing an aberrant expression of E-cadherin at the cytoplasm, exhibited no reactivity to T[α-Man] mAb. In contrast, cells 
from normal adjacent mucosa and human normal gastric mucosa characterized by a cell membrane localization of E-cadherin and almost 
no expression of β1,6 GlcNAc branched N-glycans, were positive to T[α-Man] mAb. Original magnification: 400x (B1) Evaluation of 
O-mannosyl glycans/ β1,6 GlcNAc branched glycans interplay (n=10 healthy patients; n= 18 diffuse gastric carcinoma patients). (B2) 
β1,6 GlcNAc branched glycans expression in total tissue lysate from normal gastric mucosa and diffuse gastric carcinoma. An increased 
expression of β1,6 GlcNAc branched N-glycans detected by L-PHA lectin blotting was verified in total tissue lysate from diffuse gastric 
carcinoma. Blot represents two independent biological experiments.
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very low levels (<10%) of β1,6 GlcNAc branched N-
glycans (as detected with L-PHA lectin) (Figure 6B-B1). 
On the other hand, neoplastic cells with an abnormal 
pattern of E-cadherin expression, showed high levels 
of β1,6 GlcNAc-branched N-glycans concomitantly 
with negligible expression of O-mannosylated proteins 
(p value=0.03). Cells from normal adjacent mucosa with 
a cell membrane localization of E-cadherin exhibited no 
reactivity to L-PHA together with positivity to T[α-Man] 
mAb. Additionally, L-PHA lectin blotting represented 
in Figure 6B2 demonstrated higher expression of 
β1,6 GlcNAc branched N-glycans on diffuse gastric 
cancer lysates, when compared with normal gastric 
mucosa. These results strongly indicated the existence 
of a significant inverse correlation between protein 
O-mannosylation and β1,6 GlcNAc branched N-glycans 
that accompany gastric carcinogenesis. (Figure 6B1).
Overall, these results support the existence 
of biological interplay between GnT-V-mediated 
glycosylation and O-mannosylation affecting the functions 
of a key tumor suppressor protein in diffuse gastric 
carcinogenesis, E-cadherin.
DISCUSSION
Dysregulation of E-cadherin is a molecular signature 
of epithelial cancer progression and glycosylation post-
translational modifications are a fundamental mechanism 
described to regulate E-cadherin functions [12]. The 
molecular mechanisms that regulate E-cadherin functions 
in cancer through the newly described O-mannosyl glycans 
is far from being elucidated [35]. Moreover, the potential 
interplay between the two major forms of E-cadherin 
post-translational modifications, N-glycosylation and 
O-mannosylation, and its relevance in cancer biology is 
completely unknown.
In this study we have demonstrated that protein 
O-mannosylation in human gastric cancer patients is 
overall reduced, suggesting that the O-mannosylation 
profile of several glycoproteins are changed affecting 
thereby the cellular regulation. Particularly, we found 
that E-cadherin undergoes a decreased O-mannosylation 
in cancer that resulted in the impairment of E-cadherin 
functions in cancer cells through interfering in its 
cell membrane localization and in the assembly and 
competence of adherens junctions. A novel functional 
link between the dysregulation of the tumour suppressor 
protein E-cadherin and the reduced expression of 
O-mannosyl glycans is thus established. Interestingly, 
when O-mannosylation was promoted in a gastric cancer 
context, a recovery of E-cadherin membrane localization 
together with an increased stability of the intercellular 
adhesive complex was observed.
We also provide new evidence for the existence 
of a yet uncovered interplay between O-mannosylation 
and N-glycosylation in human gastric carcinogenesis 
that appears to operate in a coordinated and site-specific 
manner on E-cadherin glycoprotein. GnT-V-mediated 
branched N-glycosylation has been described to contribute 
to tumour invasiveness and metastasis, being thus an 
instrumental mechanism of E-cadherin dysregulation in 
cancer [42–44]. Indeed, modification of E-cadherin with 
β1,6 GlcNAc branched N-glycans leads to E-cadherin 
cellular mislocalization and an incorrect assembly of 
adherens-junctions, compromises cell-cell adhesion 
and downstream signalling pathways [18, 19, 45]. More 
importantly, the expression of β1,6 GlcNAc branched N-
glycans on E-cadherin is associated with poor survival 
rates of gastric cancer patients [21].
Altered POMT2 expression in gastric cancer 
cells consistently resulted in altered expression of 
branched complex N-glycans on E-cadherin in an 
inverse and coordinated manner. POMT2 knockdown 
resulted in an increased GnT-V-mediated branched N-
glycans on E-cadherin. Likewise, when the branched 
N-glycosylation pathway is induced, by overexpressing 
MGAT5, a significant decrease of O-mannosyl glycans 
attached to E-cadherin was observed. GnT-V-mediated 
N-glycosylation and O-mannosylation processes are thus 
two crucial inter-players that contribute to the E-cadherin 
functions.
In a previous work we reported that among the four 
potential N-glycosylation sites of E-cadherin, the Asn-
554 is selectively occupied with β1,6-GlcNAc-branched 
N-glycans. Preventing the addition of these branched 
N-glycans at Asn 554 resulted in a protective effect on 
E-cadherin, precluding its functional dysregulation in 
cancer [21]. In this study, we demonstrated that presence 
of the branched N-glycans at E-cadherin Asn-554 directly 
affects its O-mannosylation pattern. The prevention 
of this site-specific glycosylation modification by Asn 
mutation potentiates the O-mannosylation profile of 
E-cadherin associated with a recover of its biological 
functions. The exact mechanism behind this coordinated 
interplay between O-mannosylation and complex 
N-glycosylation on E-cadherin needs to be further 
dissected. The competition for donor mannose substrate 
in the ER; protein conformational changes; localization 
of glycosyltranferases in ER and/or Golgi compartments; 
the physio-pathological context of the tissue/cell may 
constitute potential explanations that need to be further 
investigated.
Importantly, this coordinated interplay was also 
observed in vivo, in the stomach of two different MGAT5 
transgenic mouse models. The MGAT5 knockout mice 
characterized by no GnT-V-mediated branched glycosylation 
[46] revealed a remarkable reactivity to O-mannosyl 
glycans. Conversely, MGAT5 overexpressing and wild-type 
mice with high to moderate levels of branched N-glycans 
showed reduced levels of O-mannosyl glycans. Moreover, 
and relevant from the clinical point of view, this interplay 
between the two glycosylation forms was also consistently 
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demonstrated in a series of patients with primary diffuse 
gastric carcinoma. Gastric neoplastic cells, characterized by 
an aberrant E-cadherin expression at the cytoplasm, exhibited 
increased expression of β1,6 GlcNAc branched N-glycans 
concomitantly with negligible levels of O-mannosyl glycans. 
The opposite was observed in normal gastric mucosa. These 
results strongly suggest that GnT-V-mediated glycosylation 
negatively affects protein O-mannosylation.
Taken together, our observations support a new 
mechanism of E-cadherin regulation in cancer cell biology. 
In a normal epithelial cell phenotype, E-cadherin undergoes 
a preferential O-mannosylation modification, which 
contributes to the proper adhesive functions of E-cadherin. 
In the ER lumen, POMT2/POMT1 complex catalyses 
the addition of mannose residues at the E-cadherin EC4 
domain and along the Golgi apparatus E-cadherin does not 
undergo complex branched N-glycosylation mediated by 
GnT-V. The predominance of O-mannosyl glycans rather 
than complex branched N-glycans contribute to a protective 
effect on E-cadherin, precluding its functional dysregulation 
(Figure 7). During malignant transformation, the balance 
O-mannosyl glycans/ complex branched N-glycans in 
E-cadherin is altered. In a cancer cell, both the POMT2 
gene and enzyme are downregulated and consequently the 
pattern of E-cadherin O-mannosylation decreases. Further, 
and owing to increased MGAT5 expression and GnT-V 
activity frequently observed in a cancer cell, E-cadherin is 
predominantly targeted by GnT-V-mediated glycosylation 
at the Golgi apparatus, where β1,6-GlcNAc-branched 
N-glycans are added to Asn-554 of E-cadherin. The 
presence of these deleterious branched N-glycans structures 
together with reduced levels of O-mannosyl glycans on EC4 
Figure 7: Model for the pattern of E-cadherin O-mannosylation and the interplay with GnT-V-mediated N-glycan 
branching in a cancer context. In a normal epithelial cell, E-cadherin undergoes a preferential O-mannosylation modification 
contributing to the proper adhesive functions of E-cadherin. In the ER lumen, the mannose residues are added at the E-cadherin EC4 domain 
by action of POMT2/POMT1 complex, and along the Golgi apparatus E-cadherin does not undergo complex branched N-glycosylation 
mediated by GnT-V. The predominance of O-mannosyl glycans rather than complex branched N-glycans contributes to a protective effect 
on E-cadherin. During malignant transformation, both the POMT2 gene and enzyme are downregulated and consequently the pattern 
of E-cadherin O-mannosylation decreases. Further, and owing to increased MGAT5 expression and GnT-V activity frequently observed 
in a cancer cell, E-cadherin is predominantly modified with β1,6 GlcNAc branched N-glycans at E-cadherin Asn-554. The presence of 
these deleterious branched N-glycans structures combined with reduced levels of O-mannosyl glycans on EC4 ectodomain lead to loss of 
E-cadherin suppressive functions in cancer, thus contributing to tumour progression and metastases.
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ectodomain lead to loss of E-cadherin suppressive functions 
in cancer, thus contributing to tumour progression and 
metastases (Figure 7).
Overall, this study proposes a newly identified 
mechanism of E-cadherin (dys)regulation in cancer that 
is precisely coordinated through the interplay between 
O-mannosylation and N-glycosylation machinery that 
operates at the protein site-specific level Moreover, these 
differential patterns of E-cadherin glycosylation can 
constitute promising (glyco)biomarkers for improving 
gastric cancer patients´ clinical management.
MATERIALS AND METHODS
Tissue immunohistochemistry and lectin staining
Formalin-fixed paraffin-embedded tissue from human 
normal gastric mucosa (n=10), human diffuse gastric 
cancer (n=18); both obtained from the S. João Centre 
Hospital, Porto, Portugal); MGAT5 knockout and MGAT5 
transgenic mouse stomach (n=3; C57BL/6 background; 
kindly provided by Michael Pierce´ and Eiji Miyoshi´ labs, 
respectively) were used for E-cadherin and L-PHA staining 
as previously described [18]. For immunoexpression of 
O-mannosylated protein, the sections were incubated with 
T[α1-Man]- specific monoclonal antibody (dilution 1:50) 
for one hour at RT (unpublished results). This study was 
approved by the ethical committee of Centro S. João Centre 
Hospital, Porto, Portugal and an informed consent was 
obtained for all the subjects.
Cell lines
Human gastric carcinoma cell lines MKN28, Kato III, 
and AGS cells (transfected with E-cadherin N-glycosylation 
site mutant, as previously described [21]) were grown in 
RPMI 1640 GlutaMAX supplemented with 10% fetal 
bovine serum (Gibco, Invitrogen) and 1% penicillin-
streptomycin (Gibco, Invitrogen), and maintained at 37 
°C in an atmosphere of 5% CO
2
. MKN45 gastric cell line 
stably transfected with human GnT-V and with the empty 
vector (mock cells) were cultured in the previous conditions 
under the selection of G418 (500 µg/mL) [41, 47, 48].
Cell transfection and siRNA transfection
Kato III suspension cells were transfected 
with plasmid pTW49 [49] using Lipofectamine 2000 
(Invitrogen), according to the manufacturer´s instructions. 
siRNA targeting POMT2 (ON-TARGETplus Human 
POMT2siRNA-SMARTpool) and control siRNA (ON-
TARGETplus Non-targeting pool) were purchased from 
Dharmacon. siPOMT2 (0-200 nM) was transfected into 
MKN28 cell line with Lipofectamine 2000 (Invitrogen) 
according to the manufacturer´s instructions. The 
efficiency of POMT2 knockdown was evaluated at RNA 
and protein level by quantitative Real Time- PCR (qRT-
PCR) and western blot, respectively. POMT2 knockdown 
was optimal with 80 nM of siRNA after 48h.
RNA expression and quantification
Total RNA was extracted from cell lines using TRI 
reagent (Sigma-Aldrich), according to manufacturer´s 
protocol. RNA yield and quality were determined 
spectophotometrically and 1000 ng of total RNA were 
reverse transcribed to single stranded cDNA using 
Superscript II Reverse Transcriptase and random hexamer 
primers (Invitrogen, Oregon, USA). qRT-PCR was carried 
out in triplicates using source RNA from three biological 
replicas, for the target genes POMT2, POMT1 and for 
the endogenous controls 18S and GAPDH. Data were 
analyzed by the ΔΔCT method [50].
Immunoblotting, lectin blotting
Protein lysates (20 µg) were subjected to 7.5% 
SDS-PAGE, transferred to nitrocellulose membranes 
and probed with primary antibodies: β-actin/ α-tubulin 
(previously described [18]) and polyclonal rabbit anti-
POMT2 (1:500; polyclonal serum directed against the 
ER-lumenal loop5-domain Val373-Leu470) [49]
To evaluate the expression of O-mannosyl glycans 
on E-cadherin, E-cadherin was immunoprecipitated [18] 
and digested with PNGase F (according to manufacturer´s 
protocol; New England, Biolabs) to remove N-glyans 
(overnight, 37°C) followed by lectin blotting using 
Biotinylated Concanavalin A (Con A) (1-5 µg/mL; 
Vector Laboratories). The efficiency of PNGase F was 
evaluated by comparing the mobility shift of E-cadherin 
from MKN28 and Kato III cell lines with E-cadherin 
N-glycoform M1234 naked (E-cadherin mutant with all 
potential N-glycosylation sites mutated and thus lacking 
N-glycans structures) (Supplementary Figure S3A-S3B). 
Galanthus nivalis lectin (GNA) was also used to evaluate 
the O-mannosylation profile of E-cadherin after removal 
of N-glycans by PNGaseF treatment (data not shown).
To evaluate O-GlcNAc expression on E-cadherin, 
E-cadherin immunoprecipitated was subjected to PNGase F 
digestion, and the membranes were probed with wheat germ 
agglutinin (WGA) lectin (10 µg/mL; Vector Laboratories). 
Mucin-type O-glycosylation (STn) of E-cadherin was 
evaluated by using the monoclonal antibody TKH2 (mouse 
IgG1). Expression of β1,6 GlcNAc branched N-glycans 
analysis on E-cadherin, was assessed by probing the 
membranes with L-PHA lectin (as previously described 
[18]). AGS cell line that endogenously lacks E-cadherin 
expression was used as a negative control for the E-cadherin 
immunoprecipitations (Supplementary Figure S3C).
Immunofluorescence
Cells were grown on six-well plates with 
coverslip, fixed with methanol and blocked with bovine 
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serum albumin (BSA) 5% in 1x PBS. Cells were then 
incubated with mouse anti-E-cadherin mAb (BD 
Bioscience; 1:200 diluted in BSA 5%, one hour at RT), 
and then with Alexa Fluor 488 anti-mouse (Invitrogen; 
1:500 diluted in BSA 5%; one hour of incubation in the 
dark) [18]. Immunofluorescent images were obtained 
using a Zeiss Imager.Z1 AxioCam MRm (Carl Zeiss, 
Jena, Germany).
Slow-aggregation assay
Wells of a 96-well-plate were coated with 50 μl of 
an agar (0.66% w/v; Sigma) solution. Cells (1.25 x 104 
per well) were seeded onto the agar gel in a 96-well plate. 
Experiments were carried out in triplicate.
Statistics
Statistical analyses were performed using the Graph 
Pad program (GrapPad Software, Inc., La Jola, CA, USA). 
Student´s tests were used to calculate the significance in an 
interval of 95% confidence levels. Values of P ≤ 0.05 were 
considered to be statistically significant (Student´s t-test: 
*P≤0.05; **P≤0.01; ***P≤0.001).
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